KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Non-Current Assets (2016 - 2025)

Abbott Laboratories' Non-Current Assets history spans 17 years, with the latest figure at -$26.0 billion for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 145.01% year-over-year to -$26.0 billion; the TTM value through Dec 2025 reached $67.2 billion, down 67.75%, while the annual FY2025 figure was -$26.0 billion, 145.01% down from the prior year.
  • Non-Current Assets for Q4 2025 was -$26.0 billion at Abbott Laboratories, down from $59.3 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $59.3 billion in Q3 2025 and bottomed at -$26.0 billion in Q4 2025.
  • The 5-year median for Non-Current Assets is $50.0 billion (2024), against an average of $38.5 billion.
  • The largest annual shift saw Non-Current Assets tumbled 231.6% in 2022 before it surged 393.2% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $13.1 billion in 2021, then crashed by 231.6% to -$17.2 billion in 2022, then soared by 393.2% to $50.5 billion in 2023, then rose by 14.27% to $57.8 billion in 2024, then tumbled by 145.01% to -$26.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Non-Current Assets are -$26.0 billion (Q4 2025), $59.3 billion (Q3 2025), and -$24.5 billion (Q2 2025).